(Total Views: 935)
Posted On: 11/23/2020 7:07:51 AM
Post# of 154134
This are excellent news !!!
We have now two shots at goal in COVID space. NP has delivered in good timing the 293 patients for the interim analysis.
Following O'Brien-Fleming criteria we would need a p-value of around 0.015 or less for a possible effectiveness stoppage.
The clock is ticking ...., is a good thing that the enrollment continues unabated. If the trial is stopped good; if not, we will be ready before end of year (as promised).
Go CYDY !!! Go Vyrologix !!!
Quote:
We continue to advance enrollment, without any pause to achieve the trial’s planned 390 patients and we are currently evaluating the ability to conduct an interim analysis as soon as possible. In the meantime, if the pace of enrollment we have experienced in the last two weeks continues, we will have the CD12 enrollment completed before the end of the year. These are exciting times for the Company and I am honored to be working alongside such dedicated co-workers.
We have now two shots at goal in COVID space. NP has delivered in good timing the 293 patients for the interim analysis.
Following O'Brien-Fleming criteria we would need a p-value of around 0.015 or less for a possible effectiveness stoppage.
The clock is ticking ...., is a good thing that the enrollment continues unabated. If the trial is stopped good; if not, we will be ready before end of year (as promised).
Go CYDY !!! Go Vyrologix !!!
(12)
(0)
